Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:2889081rdf:typepubmed:Citationlld:pubmed
pubmed-article:2889081lifeskim:mentionsumls-concept:C0008059lld:lifeskim
pubmed-article:2889081lifeskim:mentionsumls-concept:C0152035lld:lifeskim
pubmed-article:2889081lifeskim:mentionsumls-concept:C0008976lld:lifeskim
pubmed-article:2889081lifeskim:mentionsumls-concept:C2003941lld:lifeskim
pubmed-article:2889081pubmed:issue8564lld:pubmed
pubmed-article:2889081pubmed:dateCreated1987-11-17lld:pubmed
pubmed-article:2889081pubmed:abstractText24 Chinese children aged 1.5-5 years and positive for hepatitis B surface antigen (HBsAg), hepatitis B e antigen (HBeAg), hepatitis B virus DNA polymerase (HBV DNAp), and HBV DNA on at least three occasions in the 6 months before the trial were randomised to receive either vitamin B complex or intramuscular recombinant alpha 2-interferon (r-IFN) ('Roferon') 10 X 10(6) IU/m2 thrice weekly for 12 weeks. In all 12 subjects receiving r-IFN, HBV DNAp and HBV DNA levels fell during the course of r-IFN injections. Within 4 weeks of cessation of r-IFN injection, the HBV DNAp and HBV DNA returned to pre-trial levels except in 2 subjects, in whom loss of HBV DNAp and HBV DNA was sustained for up to 18 months from onset of the trial. 1 child lost HBeAg at 18 months. 2 of the 12 children in the placebo group also had a sustained loss of HBV DNAp and HBV DNA during the 18 months, with 1 child losing HBeAg at 18 months. All 24 subjects remained positive for HBsAg. r-IFN produced very slight side-effects except for pyrexia and the "flu" syndrome, both of which showed rapid tachyphylaxis. In the dose given r-IFN was safe but had no long-term beneficial effects on HBsAg carriage in Chinese children.lld:pubmed
pubmed-article:2889081pubmed:languageenglld:pubmed
pubmed-article:2889081pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:2889081pubmed:citationSubsetAIMlld:pubmed
pubmed-article:2889081pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:2889081pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:2889081pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:2889081pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:2889081pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:2889081pubmed:statusMEDLINElld:pubmed
pubmed-article:2889081pubmed:monthOctlld:pubmed
pubmed-article:2889081pubmed:issn0140-6736lld:pubmed
pubmed-article:2889081pubmed:authorpubmed-author:YeungC YCYlld:pubmed
pubmed-article:2889081pubmed:authorpubmed-author:LowA GAGlld:pubmed
pubmed-article:2889081pubmed:authorpubmed-author:LiuH SHSlld:pubmed
pubmed-article:2889081pubmed:authorpubmed-author:LaiC LCLlld:pubmed
pubmed-article:2889081pubmed:authorpubmed-author:WuP CPClld:pubmed
pubmed-article:2889081pubmed:authorpubmed-author:YeohE KEKlld:pubmed
pubmed-article:2889081pubmed:issnTypePrintlld:pubmed
pubmed-article:2889081pubmed:day17lld:pubmed
pubmed-article:2889081pubmed:volume2lld:pubmed
pubmed-article:2889081pubmed:ownerNLMlld:pubmed
pubmed-article:2889081pubmed:authorsCompleteYlld:pubmed
pubmed-article:2889081pubmed:pagination877-80lld:pubmed
pubmed-article:2889081pubmed:dateRevised2007-11-15lld:pubmed
pubmed-article:2889081pubmed:meshHeadingpubmed-meshheading:2889081-...lld:pubmed
pubmed-article:2889081pubmed:meshHeadingpubmed-meshheading:2889081-...lld:pubmed
pubmed-article:2889081pubmed:meshHeadingpubmed-meshheading:2889081-...lld:pubmed
pubmed-article:2889081pubmed:meshHeadingpubmed-meshheading:2889081-...lld:pubmed
pubmed-article:2889081pubmed:meshHeadingpubmed-meshheading:2889081-...lld:pubmed
pubmed-article:2889081pubmed:meshHeadingpubmed-meshheading:2889081-...lld:pubmed
pubmed-article:2889081pubmed:meshHeadingpubmed-meshheading:2889081-...lld:pubmed
pubmed-article:2889081pubmed:meshHeadingpubmed-meshheading:2889081-...lld:pubmed
pubmed-article:2889081pubmed:meshHeadingpubmed-meshheading:2889081-...lld:pubmed
pubmed-article:2889081pubmed:meshHeadingpubmed-meshheading:2889081-...lld:pubmed
pubmed-article:2889081pubmed:meshHeadingpubmed-meshheading:2889081-...lld:pubmed
pubmed-article:2889081pubmed:meshHeadingpubmed-meshheading:2889081-...lld:pubmed
pubmed-article:2889081pubmed:meshHeadingpubmed-meshheading:2889081-...lld:pubmed
pubmed-article:2889081pubmed:meshHeadingpubmed-meshheading:2889081-...lld:pubmed
pubmed-article:2889081pubmed:meshHeadingpubmed-meshheading:2889081-...lld:pubmed
pubmed-article:2889081pubmed:meshHeadingpubmed-meshheading:2889081-...lld:pubmed
pubmed-article:2889081pubmed:meshHeadingpubmed-meshheading:2889081-...lld:pubmed
pubmed-article:2889081pubmed:meshHeadingpubmed-meshheading:2889081-...lld:pubmed
pubmed-article:2889081pubmed:meshHeadingpubmed-meshheading:2889081-...lld:pubmed
pubmed-article:2889081pubmed:year1987lld:pubmed
pubmed-article:2889081pubmed:articleTitlePlacebo-controlled trial of recombinant alpha 2-interferon in Chinese HBsAg-carrier children.lld:pubmed
pubmed-article:2889081pubmed:affiliationDepartment of Medicine, University of Hong Kong, Queen Mary Hospital.lld:pubmed
pubmed-article:2889081pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:2889081pubmed:publicationTypeClinical Triallld:pubmed
pubmed-article:2889081pubmed:publicationTypeRandomized Controlled Triallld:pubmed
pubmed-article:2889081pubmed:publicationTypeResearch Support, Non-U.S. Gov'tlld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:2889081lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:2889081lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:2889081lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:2889081lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:2889081lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:2889081lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:2889081lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:2889081lld:pubmed